The DOCK11 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the DOCK11 gene. This loss-of-function model enables systematic investigation of DOCK11-dependent signaling and cellular functions without the limitations of clonal selection.
A-549 cells were originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma and exhibit an adherent epithelial morphology. They serve as a widely accepted in vitro model of type II alveolar epithelial cells and are extensively utilized in cancer biology, respiratory disease research, and drug development. Their robust growth characteristics and well-documented genomic profile make them a reliable platform for studying the molecular mechanisms underlying lung cancer progression, metastasis, and therapeutic resistance.
DOCK11 encodes a guanine nucleotide exchange factor (GEF) that specifically activates the Rho-family GTPases Cdc42 and Rac1 by catalyzing the exchange of GDP for GTP. Upon stimulation by upstream signals such as B cell receptor (BCR) engagement, chemokine receptors (CXCR4, CCR7), CD40 ligation, or interleukin-4 (IL-4), DOCK11 is recruited to the plasma membrane where it forms a complex with the adaptor protein ELMO1 to efficiently activate Rac1. Activated Cdc42 and Rac1 then trigger downstream effector cascades, including the p21-activated kinases PAK1/2, c-Jun N-terminal kinase (JNK), and the transcription factor NF-??B, ultimately driving actin polymerization through the WASP/WAVE regulatory complex. This signaling axis is central to cytoskeletal reorganization, cell migration, adhesion dynamics, and immune cell activation.
In A-549 lung adenocarcinoma cells, DOCK11-mediated activation of Cdc42 and Rac1 is anticipated to govern actin cytoskeleton remodeling, a prerequisite for cell migration and invasion. By ablating DOCK11 function in this adherent epithelial model, researchers can directly assess how loss of this GEF impacts motile and invasive properties, providing insights into metastatic mechanisms that may be mirrored in other cancer types. The system also offers a simplified background in which to dissect core DOCK11 signaling modules independent of the specialized receptor repertoire of lymphocytes.
Researchers can employ this knockout cell pool in a broad spectrum of assays to characterize DOCK11 function. Western blotting and RT-qPCR enable confirmation of DOCK11 disruption and analysis of downstream signaling components such as phospho-PAK and total JNK levels. Transwell migration and wound healing assays quantify changes in cell motility, while immunofluorescence staining for F-actin and focal adhesion markers reveals alterations in cytoskeletal architecture. GTPase activation pulldown assays directly measure Cdc42 and Rac1 activity, and co-immunoprecipitation experiments can assess the integrity of the DOCK11?CELMO1 interaction. These tools are valuable for target validation, phenotypic screening of GEF inhibitors, and mechanistic studies of signaling networks controlling lung cancer cell behavior. For detailed product information or technical support, please contact Ascent Research.
